This company is expected to post quarterly loss of $0.39 per share in its upcoming report, which represents a year-over-year change of -62.5%. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Beam Global ( BEEM Quick Quote BEEM - Free Report), has yet to report results for the quarter ended March 2023. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the bottom 35% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is $0.46 on $3.78 billion in revenues for the coming quarter and $1.94 on $15 billion in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Adient: mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Adient has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Īdient shares have added about 7.1% since the beginning of the year versus the S&P 500's gain of 7.3%. The company has topped consensus revenue estimates three times over the last four quarters. This compares to year-ago revenues of $3.51 billion. Over the last four quarters, the company has surpassed consensus EPS estimates two times.Īdient, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $3.91 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 5.24%. A quarter ago, it was expected that this automotive seating and interiors supplier would post earnings of $0.40 per share when it actually produced earnings of $0.34, delivering a surprise of -15%. This quarterly report represents an earnings surprise of -21.95%. These figures are adjusted for non-recurring items. This compares to loss of $0.13 per share a year ago. This is a 31.Adient ( ADNT Quick Quote ADNT - Free Report) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.41 per share. (BEAM) Reports Q1 Loss, Tops Revenue Estimatesīeam Therapeutics Q1 EPS $(1.33) Beats $(1.34) Estimate, Sales $24.21M Beat $14.08M Estimateīeam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.34) by 0.75 percent. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giīeam Therapeutics Is Maintained at Equal-Weight by Barclaysīeam Therapeutics Price Target Cut to $41.00/Share From $45.00 by Barclaysīarclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $41īarclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $45 to $41.īeam Therapeutics GAAP EPS of -$1.33 In-line, Revenue of $24.2M Beats by $8.56Mīeam Therapeutics Inc. RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk RatingĠ7:44 AM EDT, (MT Newswires) - RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Ratingīeam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare ConferenceĬAMBRIDGE, Mass., (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to Beam Therapeutics to Participate in Upcoming May Investor ConferencesĬAMBRIDGE, Mass., (GLOBE NEWSWIRE) - Beam Therapeutics Inc.
0 Comments
Leave a Reply. |